avail
vaccin
fail
induc
last
protect
immun
equin
herpesviru
associ
diseas
rna
interfer
novel
approach
show
promis
therapeut
use
outbreak
situat
studi
examin
effect
small
interf
rna
sirna
clinic
sign
well
presenc
live
viru
viral
dna
nasal
secret
peripher
blood
mononuclear
cell
pbmc
hors
experiment
infect
sirna
target
two
gene
glycoprotein
b
origin
bind
protein
administ
h
h
intranas
infect
control
hors
receiv
sirna
target
firefli
luciferas
significantli
smaller
proport
hors
receiv
sirna
target
viral
gene
requir
euthanasia
due
intract
neurolog
diseas
compar
hors
control
group
p
signific
differ
presenc
live
viru
viral
dna
nasal
secret
pbmc
two
group
futur
studi
necessari
defin
rel
contribut
host
viru
factor
develop
neurolog
form
infect
determin
optim
dose
regimen
metaphylact
therapeut
use
sirna
treat
infect
equin
herpesviru
type
alphaherpesviru
caus
usual
mild
respiratori
diseas
abort
neurolog
diseas
hors
harless
pusterla
clinic
ill
result
import
albeit
poorli
quantifi
impact
aspect
equin
industri
includ
reproduct
earli
neonat
loss
time
lost
train
competit
rare
case
death
viru
possess
sever
characterist
made
develop
effect
vaccin
challeng
includ
evas
host
immun
system
lytic
phase
infect
van
der
meulen
et
al
establish
latenc
host
viru
remain
dormant
attack
humor
cellular
immun
effector
slater
et
al
epidemiolog
factor
also
reduc
vaccin
efficaci
foal
often
infect
first
time
young
age
despit
presenc
matern
antibodi
gilkerson
et
al
convent
vaccin
may
mitig
clinic
sign
respiratori
diseas
abort
decreas
viral
shed
found
prevent
infect
stimul
longlast
immun
protect
neurolog
syndrom
caus
infect
equin
herp
myeloencephalopathi
ehm
goodman
et
al
patel
et
al
treatment
hors
clinic
diseas
tradit
limit
support
care
recent
antivir
drug
includ
acyclovir
valacyclovir
investig
poor
bioavail
lack
control
clinic
evid
extens
cost
treatment
preclud
wide
use
field
bentz
et
al
garr
et
al
garr
et
al
henning
et
al
maxwel
et
al
failur
convent
drug
vaccin
produc
desir
level
protect
led
investig
altern
technolog
prophylaxi
treatment
clinic
diseas
one
novel
approach
shown
promis
vitro
speci
vivo
use
rna
interfer
rna
interfer
involv
recruit
endogen
exogen
short
interf
rna
sirna
rnainduc
silenc
complex
risc
result
degrad
target
mrna
stevenson
human
diseas
vivo
studi
rhesu
macaqu
show
benefici
effect
rna
interfer
prevent
treatment
sever
acut
respiratori
syndrom
sar
coronaviru
includ
signific
decreas
fever
viral
load
lung
patholog
li
et
al
moreov
clinic
trial
human
start
use
sirna
treatment
respiratori
syncyti
viru
rsv
infect
haasnoot
et
al
equin
virus
vitro
studi
shown
sirna
reduc
viral
titer
cell
cultur
infect
equin
arter
viru
heinrich
et
al
african
hors
sick
viru
stassen
et
al
venezuelan
equin
enceph
viru
obrien
specif
rna
interfer
effect
vitro
vivo
assess
reduct
plaqu
format
cell
cultur
reduct
clinic
sign
weight
loss
viral
replic
within
lung
tissu
murin
model
infect
fulton
et
al
evid
studi
suggest
sirna
might
ideal
agent
protect
incontact
hors
outbreak
particularli
situat
comingl
hors
occur
around
time
index
case
diagnos
object
studi
test
hypothesi
metaphylact
intranas
administr
sirna
target
critic
gene
reduc
clinic
diseas
nasal
shed
viru
viremia
hors
experiment
infect
protocol
studi
approv
institut
anim
care
use
committe
cornel
univers
fourteen
hors
least
differ
breed
use
experi
includ
geld
mare
rang
age
year
one
mare
approxim
old
determin
pregnant
end
studi
inclus
criteria
serum
neutral
antibodi
sn
titer
spontan
reactiv
observ
period
prior
start
experi
hors
kept
two
differ
locat
close
herd
access
pastur
grass
hay
ad
libitum
prior
studi
previou
vaccin
histori
hors
unknown
hors
move
biosecur
isol
facil
randomli
assign
via
lotteri
treatment
control
group
allow
acclim
day
studi
conduct
blind
manner
investig
involv
laboratori
assay
clinic
evalu
remain
blind
data
gather
sampl
fulli
process
conclus
studi
sampl
laboratori
assay
includ
blood
nasal
swab
obtain
day
physic
examin
includ
neurolog
score
perform
twice
day
first
h
postinfect
pi
day
daili
day
physic
neurolog
examin
perform
two
equin
clinician
accord
commonli
use
clinic
score
system
fever
defin
rectal
temperatur
c
neurolog
score
rang
grade
neurolog
deficit
grade
recumb
inabl
rise
furr
reed
unaccept
suffer
occur
recumb
inabl
perform
normal
bodi
function
eat
drink
urin
defec
hors
euthan
immedi
postmortem
examin
perform
day
pi
remain
hors
euthan
sirna
use
studi
describ
previous
target
gene
encod
glycoprotein
b
requir
viral
entri
celltocel
transmiss
origin
bind
protein
helicas
requir
replic
viral
genom
fulton
et
al
control
hors
receiv
irrelev
sirna
target
firefli
luciferas
siluc
sirna
reconstitut
accord
manufactur
instruct
ambion
austin
tx
dilut
phosphatebuff
salin
pb
hors
sedat
detomidin
mgkg
iv
prior
intranas
sirna
treatment
infect
treatment
hors
receiv
mixtur
sirna
consist
pmol
intranas
use
mucos
atom
devic
wolf
tori
medic
salt
lake
citi
ut
dose
administ
total
volum
ml
ml
nostril
metaphylact
administr
sirna
perform
h
prior
h
infect
day
control
hors
receiv
equal
amount
irrelev
siluc
pmol
administ
way
treat
group
hors
infect
intranas
plaqueform
unit
pfu
strain
viru
goodman
et
al
use
applic
techniqu
sirna
strain
possess
singl
nucleotid
polymorph
snp
polymeras
gene
frequent
associ
develop
ehm
strain
lack
mutat
nugent
et
al
blood
drawn
serum
tube
tube
contain
sodium
heparin
tyco
healthcar
group
mansfield
sampl
day
blood
serum
tube
allow
clot
centrifug
g
c
min
serum
collect
frozen
c
determin
serum
neutral
titer
peripher
blood
mononuclear
cell
pbmc
isol
heparin
blood
use
histopaqu
sigma
aldrich
st
loui
mo
recommend
supplier
aliquot
use
immedi
viru
isol
cocultiv
cell
describ
remain
pbmc
frozen
c
subsequ
qpcr
process
nasal
swab
obtain
use
two
steril
polyestertip
swab
puritan
medic
product
compani
llc
guilford
place
directli
polystyren
tube
contain
ml
viral
transport
medium
neonat
calf
serum
pb
supplement
antibioticantimycot
solut
uml
penicillin
gml
streptomycin
gml
amphotericin
b
gml
enrofloxacin
nasal
swab
immedi
place
ice
chill
h
centrifug
g
min
c
aliquot
use
immedi
viral
titrat
cell
describ
remain
sampl
frozen
c
subsequ
qpcr
process
final
cerebrospin
fluid
csf
sampl
collect
atlantooccipit
space
immedi
follow
euthanasia
place
edta
tube
cytolog
tube
without
anticoagul
aliquot
submit
immedi
cytolog
remaind
store
c
qprc
addit
complet
postmortem
examin
perform
hors
euthan
follow
develop
neurolog
sign
viru
isol
titrat
perform
use
rabbit
kidney
cell
monolay
maintain
minimum
essenti
medium
mem
mediatech
herndon
va
supplement
fb
gemini
bioproduct
west
sacramento
ca
penicillin
streptomycin
amphotericin
b
solut
mediatech
herndon
va
plate
pbmc
cocultiv
l
aliquot
pbmc
appli
monolayercontain
well
l
medium
three
subsequ
dilut
made
plate
examin
daili
evalu
presenc
viral
cytopath
effect
cpe
plate
record
posit
neg
nasal
swab
l
nasal
swab
fluid
appli
monolay
plate
three
subsequ
dilut
made
medium
remov
h
replac
fresh
medium
contain
methylcellulos
sigma
st
loui
mo
plate
examin
daili
cpe
day
incub
cell
fix
aceton
stain
crystal
violet
plaqu
count
viral
titer
calcul
dna
extract
pbmc
nasal
swab
csf
ez
omega
norcross
ga
tissu
dneasi
qiagen
germantown
md
done
use
commerci
avail
kit
qpcr
perform
appli
biosystem
fast
real
time
pcr
system
foster
citi
ca
protocol
includ
initi
stage
run
c
follow
cycl
c
c
total
volum
per
well
l
includ
l
perfecta
pcr
fast
mix
quanta
bioscienc
gaithersburg
md
l
forward
revers
primer
l
probe
l
h
l
dna
target
viral
gene
genom
copi
pbmc
normal
use
primer
probe
equin
goodman
et
al
goodman
et
al
genom
copi
nasal
swab
normal
ad
standard
number
marek
diseas
viru
mdv
genom
copi
bac
clone
lysi
buffer
target
mdv
gene
jarosinski
et
al
previous
describ
perkin
et
al
statistix
sa
version
use
perform
statist
analys
data
set
first
evalu
normal
distribut
use
kolmogorovsmirnov
test
determin
data
normal
distribut
nonparametr
test
includ
fisher
exact
test
wilcoxon
ranksum
test
use
subsequ
analysi
statist
test
group
three
set
clinic
sign
live
viru
viral
dna
nasal
secret
live
viru
viral
dna
pbmc
comparison
siluc
versu
anim
one
addit
set
compar
serum
neutral
titer
viral
load
pbmc
neurolog
versu
nonneurolog
hors
irrespect
treatment
group
perform
bonferroni
correct
interpret
p
valu
set
group
treat
sirna
includ
mare
geld
averag
estim
age
year
rang
median
siluc
control
group
includ
mare
geld
averag
estim
age
year
rang
median
signific
differ
group
begin
studi
treatment
result
significantli
lower
proport
hors
requir
euthanasia
intract
neurolog
diseas
hors
develop
serou
nasal
discharg
characterist
acut
infect
within
h
pi
also
biphas
increas
temperatur
observ
first
peak
day
pi
reach
c
second
peak
day
pi
fig
signific
differ
observ
peak
temperatur
p
total
number
day
fever
p
two
group
neurolog
sign
develop
siluc
hors
hors
sign
neurolog
diseas
first
fig
mean
rectal
temperatur
hors
intranas
administ
siluc
h
h
infect
arrow
fever
consid
c
indic
dot
line
note
biphas
natur
temperatur
increas
modest
increas
second
peak
typic
neurovirul
observ
day
one
hors
group
fig
siluc
hors
becam
neurolog
met
criteria
euthanasia
becam
recumb
one
unabl
urin
none
hors
proport
hors
develop
neurolog
sign
significantli
differ
siluc
group
p
hors
siluc
control
group
higher
median
neurolog
score
p
retain
signific
bonferroni
correct
appli
differ
proport
hors
group
meet
criteria
euthanasia
signific
p
retain
signific
bonferroni
correct
data
csf
cytolog
detect
viral
genom
copi
qpcr
csf
spinal
cord
hors
develop
neurolog
sign
summar
tabl
hors
group
grade
ataxia
conclus
studi
detect
gross
histopatholog
cen
fig
neurolog
score
day
day
infect
neurolog
sign
note
hors
day
pi
symbol
repres
hors
solid
shape
siluctr
hors
n
develop
neurolog
sign
open
shape
hors
n
develop
neurolog
sign
hors
develop
neurolog
sign
given
color
black
asterisk
indic
day
hors
human
euthan
due
sever
ehm
signific
differ
proport
hors
develop
neurolog
sign
requir
euthanasia
control
group
p
interpret
refer
color
figur
caption
reader
refer
web
version
articl
tral
nervou
system
abnorm
multifoc
mildtomoder
lymphocyt
encephalomyel
vascul
consist
ehm
note
postmortem
examin
hors
euthan
due
sever
neurolog
symptom
immunohistochemistri
detect
abund
antigen
within
individu
endotheli
cell
area
vascul
hors
test
data
shown
hors
group
secret
viru
day
pi
detect
titrat
cell
fig
qpcr
presenc
dna
nasal
secret
detect
hors
group
day
pi
day
pi
fig
signific
differ
peak
viru
isol
median
pfuml
day
posit
viru
isol
nasal
secret
two
group
peak
number
genom
copiesml
significantli
higher
siluc
group
p
although
retain
signific
bonferroni
correct
base
pbmc
cocultiv
result
sever
hors
group
virem
day
pi
day
pi
hors
becam
posit
fig
quantit
pcr
show
presenc
genom
copi
pbmc
day
pi
day
pi
hors
group
fig
signific
differ
peak
number
genom
p
number
qpcr
posit
day
two
group
p
peak
sn
titer
p
peak
genom
p
neurolog
nonneurolog
hors
irrespect
treatment
group
show
signific
differ
rna
interfer
studi
extens
research
tool
recent
therapeut
potenti
treat
cancer
viral
diseas
numer
studi
shown
efficaci
mitig
effect
viral
infect
vitro
vivo
author
knowledg
studi
repres
first
attempt
open
bar
n
signific
differ
group
bonferroni
correct
b
qpcr
pbmc
express
median
genom
copi
per
million
copi
solid
bar
siluc
control
n
open
bar
n
signific
differ
group
sole
surviv
hors
siluc
group
virem
day
pi
employ
rna
interfer
vivo
hors
experiment
model
use
studi
close
resembl
occur
field
outbreak
situat
sever
respect
popul
contain
hors
variou
age
breed
gender
pregnanc
statu
like
differ
histori
vaccin
exposur
treatment
protocol
metaphylact
ensu
time
index
case
diagnos
onset
outbreak
henning
et
al
howev
use
nonuniform
experiment
popul
well
intrins
natur
infect
hors
introduc
studi
potenti
confound
factor
summar
briefli
experiment
field
studi
suggest
number
horserel
characterist
notabl
age
immun
statu
influenc
natur
sever
diseas
result
infect
allen
henning
et
al
factor
either
control
known
studi
might
influenc
result
way
quantifi
epidemiolog
characterist
infect
also
introduc
potenti
variabl
endem
equin
popul
worldwid
infect
foal
young
age
foot
et
al
establish
latent
infect
recrudesc
time
stress
slater
et
al
stress
associ
transport
studi
hors
herd
set
isol
unit
might
caus
recrudesc
latent
viru
possibl
confound
result
although
examin
statu
hors
exclud
acut
recrudesc
sn
titer
clinic
observ
reactiv
latent
viru
sever
express
diseas
coinfect
formal
exclud
random
alloc
hors
would
help
distribut
confound
evenli
two
group
often
case
vivo
larg
anim
studi
small
sampl
size
made
statist
analysi
challeng
small
sampl
size
siluc
control
group
affect
fact
three
four
hors
group
requir
euthanasia
prior
end
studi
group
impact
made
one
hors
show
unexpectedli
sever
unusu
cours
challeng
infect
day
pi
hors
develop
nasal
discharg
charact
volum
differ
observ
hors
typic
infect
mucopurul
bloodting
nasal
discharg
produc
larg
amount
time
nasopharyng
swab
obtain
cultur
streptococcu
equi
subspeci
equi
neg
addit
nasal
swab
submandibular
lymph
node
sampl
obtain
postmortem
neg
equi
pcr
nasal
swab
neg
equin
influenza
pcr
viru
isol
hors
sequenc
ident
strain
administ
studi
hors
one
two
hors
develop
neurolog
diseas
alon
account
extend
viru
isol
pbmc
day
group
unabl
document
intercurr
diseas
viral
recrudesc
viral
mutat
justifi
subject
exclus
impact
one
hors
unusu
sever
sign
much
greater
would
larger
popul
hypothes
treatment
sirna
import
gene
would
lessen
clinic
sign
well
presenc
live
viru
viral
dna
nasal
secret
pbmc
develop
intract
neurolog
diseas
necessit
euthanasia
significantli
reduc
group
unexpectedli
presenc
live
viru
nasal
secret
pbmc
presenc
viral
dna
pbmc
remain
unaffect
peak
content
viral
dna
nasal
secret
lower
group
although
retain
signific
bonferroni
correct
lend
support
valu
studi
use
sirna
prior
studi
includ
field
outbreak
experiment
infect
shown
relationship
develop
neurolog
sign
increas
biphas
temperatur
magnitud
durat
lymphocyteassoci
viremia
allen
breathnach
henning
et
al
infect
neurovirul
strain
result
higher
level
viremia
compar
nonneurovirul
strain
allen
breathnach
singl
nucleotid
polymorph
snp
dna
polymeras
gene
identifi
account
increas
level
viremia
goodman
et
al
nugent
et
al
van
de
wall
et
al
characterist
host
immun
system
includ
slow
rise
specif
antibodi
titer
low
concentr
specif
cytotox
tlymphocyt
prior
infect
also
implic
risk
factor
hors
develop
ehm
allen
allen
breathnach
henning
et
al
hors
studi
inocul
strain
neurovirul
expect
temperatur
viremia
would
decreas
group
find
present
studi
show
neurolog
diseas
mitig
hors
specif
sirna
compar
control
group
signific
reduct
viremia
temperatur
observ
upon
treatment
also
differ
viremia
sn
titer
neurolog
versu
nonneurolog
hors
irrespect
treatment
hors
receiv
data
consid
togeth
suggest
much
complex
pathogenesi
ehm
current
understand
provid
major
find
neurolog
diseas
significantli
decreas
specif
sirna
treat
hors
highli
desir
outcom
must
interpret
caution
reproduc
result
experi
host
factor
intens
monitor
control
would
provid
addit
support
effect
rna
interfer
suitabl
therapi
combat
infect
presum
mechan
action
intranas
appli
sirna
uptak
nasal
epithelium
inhibit
initi
viral
replic
halt
diseas
progress
port
viral
entri
much
remain
learn
cellular
uptak
intracellular
kinet
sirna
factor
thought
influenc
durat
effect
sirna
includ
rate
cell
divis
degrad
sirna
endogen
nucleas
one
vivo
murin
studi
look
factor
siluc
show
activ
week
nondivid
liver
cell
day
rapidli
divid
tumor
cell
bartlett
davi
current
data
pertain
kinet
specif
sirna
equin
epitheli
cell
new
research
conduct
effect
administr
protocol
gradual
improv
potenti
improv
sirna
therapi
combat
respiratori
virus
includ
follow
chemic
modif
sirna
improv
vivo
stabil
potenc
test
variou
carrier
optim
deliveri
absorpt
stabil
combin
sirna
eg
decongest
especi
nasal
discharg
present
modif
dose
regimen
includ
higher
andor
frequent
dose
altern
techniqu
administr
finer
aerosol
current
experi
plan
chemic
modifi
sirna
evalu
experiment
hors
administ
higher
intranas
dose
everi
h
day
near
futur
summari
studi
present
result
first
attempt
use
rna
interfer
goal
decreas
clinic
diseas
viral
shed
cellassoci
viremia
due
infect
hors
although
signific
differ
viral
shed
viremia
treat
control
group
euthanasia
necessit
intract
neurolog
sign
significantli
reduc
applic
specif
sirna
shown
previous
interfer
viru
replic
vitro
murin
model
infect
fulton
et
al
given
success
seen
thu
far
use
sirna
model
respiratori
diseas
believ
modif
sirna
andor
dose
regimen
use
studi
would
result
improv
outcom
respect
viremia
viru
shed
move
toward
ultim
goal
effect
sirna
treatment
devast
diseas
although
progress
made
recent
year
toward
better
understand
diseas
addit
research
elucid
rel
contribut
viral
host
environment
factor
clearli
warrant
none
